26.27
0.19%
-0.05
After Hours:
26.20
-0.07
-0.27%
Overview
News
Price History
Option Chain
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc. stock is currently priced at $26.27, with a 24-hour trading volume of 22.87M.
It has seen a -0.19% decreased in the last 24 hours and a -3.98% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $26.33 pivot point. If it approaches the $26.18 support level, significant changes may occur.
Previous Close:
$26.32
Open:
$26.25
24h Volume:
22.87M
Market Cap:
$148.75B
Revenue:
$58.50B
Net Income/Loss:
$2.12B
P/E Ratio:
14.36
EPS:
1.83
Net Cash Flow:
$4.79B
1W Performance:
+3.34%
1M Performance:
-3.98%
6M Performance:
-13.67%
1Y Performance:
-34.18%
Pfizer Inc. Stock (PFE) Company Profile
Name
Pfizer Inc.
Sector
Industry
Phone
212-733-2323
Address
235 East 42nd Street, New York, NY
Pfizer Inc. Stock (PFE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Oct-20-23 | Resumed | UBS | Neutral |
Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
Jul-17-23 | Reiterated | JP Morgan | Neutral |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mar-06-23 | Initiated | Jefferies | Hold |
Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
Jan-26-23 | Downgrade | UBS | Buy → Neutral |
Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
Nov-18-22 | Initiated | Credit Suisse | Outperform |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
Dec-20-21 | Reiterated | Cowen | Outperform |
Dec-17-21 | Initiated | Goldman | Neutral |
Dec-13-21 | Upgrade | UBS | Neutral → Buy |
Dec-09-21 | Initiated | Wells Fargo | Overweight |
Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
Jul-27-21 | Resumed | Truist | Buy |
May-06-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-19-20 | Resumed | Goldman | Neutral |
Nov-10-20 | Resumed | Bernstein | Mkt Perform |
Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
Sep-29-20 | Initiated | Berenberg | Hold |
Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
Feb-06-20 | Initiated | Mizuho | Buy |
Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-04-19 | Resumed | Morgan Stanley | Overweight |
Feb-20-19 | Resumed | Citigroup | Neutral |
Jan-31-19 | Upgrade | Argus | Hold → Buy |
Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-23-19 | Downgrade | UBS | Buy → Neutral |
Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc. Stock (PFE) Latest News
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Zacks Investment Research
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Better Buy: Pfizer vs. Viking Therapeutics
The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
The Motley Fool
Pfizer (PFE) Rises Higher Than Market: Key Facts
Zacks Investment Research
Some Bubbles Are Starting To Pop
Seeking Alpha
Pfizer Inc. Stock (PFE) Financials Data
Pfizer Inc. (PFE) Revenue 2024
PFE reported a revenue (TTM) of $58.50 billion for the quarter ending December 31, 2023, a -41.70% decline year-over-year.
Pfizer Inc. (PFE) Net Income 2024
PFE net income (TTM) was $2.12 billion for the quarter ending December 31, 2023, a -93.25% decrease year-over-year.
Pfizer Inc. (PFE) Cash Flow 2024
PFE recorded a free cash flow (TTM) of $4.79 billion for the quarter ending December 31, 2023, a -81.59% decrease year-over-year.
Pfizer Inc. (PFE) Earnings per Share 2024
PFE earnings per share (TTM) was $0.36 for the quarter ending December 31, 2023, a -93.43% decline year-over-year.
Pfizer Inc. Stock (PFE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BOURLA ALBERT | Chairman & CEO |
Feb 23 '24 |
Option Exercise |
27.34 |
127,674 |
3,490,607 |
439,748 |
LANKLER DOUGLAS M | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
95,755 |
2,617,942 |
230,920 |
SUSMAN SALLY | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
63,837 |
1,745,304 |
218,148 |
JOHNSON RADY A | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
29,436 |
804,780 |
123,073 |
McDermott Michael | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
12,412 |
339,344 |
95,408 |
SAHNI PAYAL | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
11,527 |
315,148 |
34,604 |
DAMICO JENNIFER B. | SVP & Controller |
Feb 23 '24 |
Option Exercise |
27.34 |
9,752 |
266,620 |
19,228 |
BOSHOFF CHRISTOFFEL | Executive Vice President |
Feb 23 '24 |
Option Exercise |
27.34 |
9,752 |
266,620 |
148,703 |
Gottlieb Scott | Director |
Dec 15 '23 |
Buy |
26.47 |
3,000 |
79,401 |
9,000 |
Gottlieb Scott | Director |
May 08 '23 |
Buy |
38.58 |
1,000 |
38,580 |
6,000 |
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; and Zenith Epigenetics Ltd., as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.
Cap:
|
Volume (24h):